Nachrichten zur Halozyme Therapeutics Inc. Aktie

Halozyme (HALO) Q1 2026 Earnings Transcript

Image source: The Motley Fool.DateMonday, May 11, 2026 at 4:30 p.m. ETCall participantsChief Executive Officer — Helen TorleyInterim Chief Financial…

Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the…

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +3.73% and +5.31%, respectively, for the quarter ended March 2026. Do…

Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Halozyme Therapeutics (HALO) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

ACHV: Change of Command Brings Material Funding

By John Vandermosten, CFANASDAQ: ACHVAchieve Life Sciences, Inc. (NASDAQ: ACHV) generated significant news flow in April, announcing the arrival of…

Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness

Halozyme Therapeutics (NasdaqGS:HALO) has appointed David Ramsay as Interim Chief Financial Officer. Ramsay, a former finance leader at the company…

Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript

…

Heres What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2025,…

Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -111.16% and +0.70%, respectively, for the quarter ended December 2025. Do…

Halozyme Therapeutics Q4 2025 Earnings Preview

…

Heres Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts…

Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth

Halozyme Therapeutics (HALO) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Halozyme: Der „Mautbetreiber“ der Biotech-Welt

Cashflow statt Forschungsrisiko:  Dank eines einzigartigen Lizenzmodells profitiert Halozyme von den Erfolgen der Pharmariesen, ohne die Milliardenrisiken eigener klinischer…

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…

Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty

Could Halozyme Therapeutics be the next big opportunity in biotech? Join our experts as they dissect the companys strengths and…

Are Medical Stocks Lagging Ardelyx (ARDX) This Year?

Here is how Ardelyx (ARDX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.…

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript

…

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Halozyme Therapeutics completes $1.5 billion convertible notes offering By Investing.com

Halozyme Therapeutics completes $1.5 billion convertible notes offering…

Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended September 2025,…

Halozyme (HALO) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool.DATEMonday, Nov. 3, 2025 at 4:30 p.m. ETCALL PARTICIPANTSPresident and Chief Executive Officer — Helen TorleySenior…

Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +5.52% and +5.10%, respectively, for the quarter ended September 2025. Do…

Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Weeks Release

Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…

Heres Why Halozyme Therapeutics (HALO) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Halozyme Therapeutics, Inc. (HALO) Discusses To Acquire Elektrofi Conference Call (Transcript)

…

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Halozyme Therapeutics and Synopsys have been highlighted as Zacks Bull and Bear of the Day

Halozyme shines with strong growth and partnerships, while Synopsys struggles after earnings miss and lowered outlook.…

Halozyme Therapeutics Aktie: Mega-Katalysator durch FDA-Zulassung - Kursziel auf 85 Dollar erhöht

New York (www.aktiencheck.de) - Halozyme Therapeutics-Aktienanalyse von H.C. Wainwright & Co.:Die Analysten von H.C. Wainwright haben das Kursziel für die…

Bull of the Day: Halozyme Therapeutics (HALO)

The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth…

Halozyme Therapeutics stock hits all-time high at 77.6 USD By Investing.com

Halozyme Therapeutics stock hits all-time high at 77.6 USD…

Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should Know

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Lets find out.…

Halozyme Therapeutics - ENHANZE-Lizenzeinnahmen schieben Ergebnis deutlich an!

Geschäftstreiber: Der US-Biotechkonzern Halozyme Therapeutics (HALO) hat sich auf Produkte im Bereich proprietäre Enzymtechnologie spezialisiert. Die von Halozyme entwickelte ENHANZE-Technologie…

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter…

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do…

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Heres Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.…

Halozyme Therapeutics - ENHANZE-Lizenzeinnahmen sorgen für neue Rekorde bei Umsatz und Ergebnis!

Geschäftstreiber: Der US-Biotechkonzern Halozyme Therapeutics (HALO) hat sich auf Produkte im Bereich proprietäre Enzymtechnologie spezialisiert. Die von Halozyme entwickelte ENHANZE-Technologie…

Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

3 Reasons Why Growth Investors Shouldnt Overlook Halozyme Therapeutics (HALO)

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.…

Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Lets find out.…

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…